Intranasal administration of guanidinylated aminoglycosides

US10543283B2 · kind B2 · utility

Assignee

• The Regents of the University of California · US

Inventors

• Jeffrey D. Esko · San Diego, US
• Yitzhak Tor · Rehovot, IL
• Wenyong Tong · San Diego, US

Key dates

• Filing date: Sep 6, 2017
• Grant date: Jan 28, 2020
• Expiry date: Aug 2, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Y310/01001
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This disclosure relates to intranasal administration of conjugates comprising guanidinylated aminoglycosides (“guanidinoglycosides”) and a polypeptide (e.g., an enzyme, antibody, or polypeptide growth factor). For example, such administration methods are useful for delivering a polypeptide to the brain and/or cerebrospinal fluid. Such methods are useful for treating a lysosomal storage disease through intranasal administration of a conjugate comprising one or more guanidinoglycosides and an enzyme useful for treating a lysosomal storage disease.